CTTC staff members work diligently to manage all disclosures and requests in a timely manner. Below is a sampling of the activity that has taken place in our office over the past few weeks:
an exclusive license with a startup company for the polymeric nanoparticles developed by Eva Harth in the Department of Chemistry
Hosted a lunch and learn event for Vanderbilt researchers to learn about KeraFAST's Investigator's Annexe Program that markets and distributes university research tools.
an exclusive license agreement with a startup company for the use of My Cancer Genome developed by William Pao and Mia Levy of Vanderbilt-Ingram Cancer Center
opportunities for commercialization of insect repellent technologies, developed by Larry Zwiebel in the Department of Biological Sciences
, with a potential partner and with a potential end-user company.
in a teleconference with a pharmaceutical company regarding phospholipase D (PLD) inhibitor compounds developed by Alex Brown and Craig Lindsley in the Center for Neuroscience Drug Discovery
the development and licensing of a diagnostic test to measure risk of pulmonary hypertension in cattle with a company that specializes in animal health testing. The technology was developed by John Newman in the Division of Allergy, Pulmonary and Critical Care Medicine
Entered a confidentiality agreement with a small biotech company interested in exploring commercialization potential of a soluble protein from a probiotic bacteria that shows protective effects in mouse model of colitis, developed by Fang Yan in Pediatric Gastroenterology and Brent Polk, Professor and Chairman of Pediatrics, Saban Research Institute Children's Hospital Los Angeles.
Participated in a webinar that discussed effective strategies for managing milestones for university startups.
Hosted a "how-to" course for developing a business strategy to students participating in the 2014 Tech Venture Challenge.